Findings lay groundwork for human clinical trial planned for August 2016
A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it. Over one million men and women are living with colorectal cancer in the United States. The National Cancer Institute estimates 4.5% of all men and women will be diagnosed with the cancer during their lifetime, making it the third most common non-skin cancer.
In the study published online in Nature Communications, researchers showed how certain colorectal cancer cells reprogram their metabolism using glutamine, a non-essential amino acid. Many cancer cells rely on glutamine to survive. How they become so dependent on the molecule is hotly debated in the field.
Researchers studied a subset of colorectal cancer cells containing a genetic mutation called PIK3CA. This mutation is located in a gene critical for cell division and movement, and is found in approximately one third of all colorectal cancers. The mutation is also the most commonly identified genetic mutation across all cancers, making the results of the study universally appealing.
Researchers were interested in determining whether or not the common PIK3CA mutation contributes to changes in cancer cell metabolism, such as how nutrients like glutamine are processed. Normally, glutamine is broken down by cancer cells into several other molecules with the help of specific enzymes. This complicated system helps produce adenosine triphosphate, the energy currency of all cells, and other molecules critical for colorectal cancer cell growth.
The researchers found that colorectal cells with the PIK3CA mutation broke down significantly more glutamine than cells without the mutation. The researchers identified several enzymes involved in the process that are more active in the mutant cancer cells than in other cell types, explaining the increased need for glutamine. These enzymes become overactive in the mutant cancer cells due to a cascade of signals led by the protein encoded by mutant PIK3CA gene. This finding represents a novel and important link between the common PIK3CA mutation and altered glutamine metabolism in cancer cells.
Zhenghe John Wang, PhD, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University School of Medicine helped lead the study. “In layman’s terms, we discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs.”
When the researchers lowered the amount of glutamine available to mutant cancer cells growing in laboratory dishes, the cancer cells died. This discovery led the team to investigate the effects of blocking glutamine availability in mice with colorectal cancer tumors containing the common PIK3CA mutation. Wang and colleagues found that exposing these mice to a compound that blocks glutamine metabolism consistently suppressed tumor growth. They did not observe the same effect on tumors without the mutation. Together, these results provide a promising new therapeutic avenue to suppress growth of colorectal tumors with the PIK3CA mutation. The researchers have filed a patent application based on the unique mechanism of tumor suppression they have identified and the work is available for licensing.
“This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center,” according to Neal Meropol, MD, Dr. Lester E. Coleman, Jr. Professor of Cancer Research and Therapeutics, chief of the division of hematology and oncology, and principal investigator for the trial. The phase I/II study will test the effects of a glutamine metabolism inhibitor in patients with advanced colorectal tumors.
The Latest on: Colorectal cancers
via Google News
The Latest on: Colorectal cancers
- Global analysis finds early onset colorectal cancer rising in many high-income countrieson September 6, 2019 at 6:46 am
A new study finds that colorectal cancer (CRC) incidence is increasing exclusively in young adults in nine high-income countries spanning three continents. A new American Cancer Society study finds ...
- Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal canceron September 5, 2019 at 3:11 pm
CD3 + and CD8 + T-cell infiltration were reported as positive predictive markers of survival in colorectal cancer (CRC) patients. Here, we demonstrate the prognostic significance of CD4 + and FOXP3 + ...
- Colon cancer rates rise among young adults in wealthy nationson September 5, 2019 at 2:10 pm
Colon cancer rates among young adults are on the rise in the United States, Canada and seven other wealthy nations, even though rates among older adults are down or stable, a new study finds. The ...
- Immunotherapy for Colon Canceron September 4, 2019 at 5:00 pm
This year it’s estimated that more than 100,000 new cases of colon cancer and an estimated 44,180 new cases of rectal cancer will be diagnosed in the U.S., according to the American Cancer Society.
- Here’s How Much Physical Activity a Day Cuts Your Risk of Colon Canceron September 2, 2019 at 6:01 am
Think back to what you were doing as a teen. Were you on the pounding the trails on the cross-country team? Maybe sprinting back and forth on the soccer field? How active you were then—and how you’ve ...
- Providing more testing choices does not increase colorectal cancer screening rateson August 30, 2019 at 8:04 am
Offering patients the choice between home screening or in-office colonoscopy does not increase participation in colorectal cancer screening, according to a new Penn Medicine study. However, the ...
- Exercise is good medicine for advanced colon canceron August 29, 2019 at 6:25 am
Waging a successful battle against advanced colon cancer should include regular doses of exercise, a new study suggests. It found that physical activity was associated with slower cancer progression ...
- Global In-vitro Colorectal Cancer Screening Tests Market 2019: Abbott Molecular Inc, Alere Inc, Beckman Coulter Incon August 28, 2019 at 10:27 pm
Aug 29, 2019 (Eon Market Research via COMTEX) -- The Global In-vitro Colorectal Cancer Screening Tests Industry 2019 Market Research Report is an expert and in-depth study on the modern state of the ...
- New Study Shows French Grape Seed VX1 Overcomes Chemoresistance in Colorectal Cancer Cellson August 28, 2019 at 12:40 pm
DUARTE, Calif., Aug. 28, 2019 /PRNewswire/ -- Dr. Ajay Goel, PhD. and his team of researchers found that administering French Grape Seed VX1 along with chemotherapy drugs helps overcome ...
- OPCs in French Grape Seed VX1 Block Multiple Tumor Pathways to Defeat Colorectal Canceron August 28, 2019 at 9:04 am
DUARTE, Calif., Aug. 28, 2019 /PRNewswire/ -- A scientific study published in the journal Carcinogenesis revealed that the OPCs in French Grape Seed VX1 exhibit multiple anticancer properties ...
via Bing News